May 27 2024 12:00:23 — Fresenius Kabi’s denosumab biosimilar BLA for osteoporosis and cancer-related bone loss treatment accepted by FDA for review.
This BLA submission acceptance is the latest development in Fresenius Kabi’s continuing commitment to improving patient access to high-quality biological products through expanding its biosimilars development capabilities and product portfolio.